EA201071309A1 - Твердая фармацевтическая композиция - Google Patents

Твердая фармацевтическая композиция

Info

Publication number
EA201071309A1
EA201071309A1 EA201071309A EA201071309A EA201071309A1 EA 201071309 A1 EA201071309 A1 EA 201071309A1 EA 201071309 A EA201071309 A EA 201071309A EA 201071309 A EA201071309 A EA 201071309A EA 201071309 A1 EA201071309 A1 EA 201071309A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
solid pharmaceutical
types
total weight
sustained release
Prior art date
Application number
EA201071309A
Other languages
English (en)
Other versions
EA022712B1 (ru
Inventor
Тадаси Мукаи
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40847022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071309(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201071309A1 publication Critical patent/EA201071309A1/ru
Publication of EA022712B1 publication Critical patent/EA022712B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к твердой фармацевтической композиции с замедленным высвобождением, содержащей (а) активный лекарственный компонент, (b) предварительно желатинизированный крахмал в количестве от 10 до 90 мас.% в расчете на общий вес композиции и (с) один или несколько типов энтеросолюбильных компонентов.
EA201071309A 2008-05-15 2009-05-14 Твердая фармацевтическая композиция EA022712B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008128259 2008-05-15
PCT/JP2009/059300 WO2009139504A2 (en) 2008-05-15 2009-05-14 A solid pharmaceutical formulation

Publications (2)

Publication Number Publication Date
EA201071309A1 true EA201071309A1 (ru) 2011-06-30
EA022712B1 EA022712B1 (ru) 2016-02-29

Family

ID=40847022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071309A EA022712B1 (ru) 2008-05-15 2009-05-14 Твердая фармацевтическая композиция

Country Status (32)

Country Link
US (1) US20110091535A1 (ru)
EP (1) EP2273981B1 (ru)
JP (1) JP5552434B2 (ru)
KR (1) KR101585280B1 (ru)
CN (2) CN104971037A (ru)
AR (1) AR071706A1 (ru)
AU (1) AU2009247156B2 (ru)
BR (1) BRPI0912656A2 (ru)
CA (1) CA2722244C (ru)
CL (1) CL2009001183A1 (ru)
CO (1) CO6321223A2 (ru)
CY (1) CY1115955T1 (ru)
DK (1) DK2273981T3 (ru)
EA (1) EA022712B1 (ru)
EC (1) ECSP10010683A (ru)
ES (1) ES2524261T3 (ru)
HK (1) HK1149497A1 (ru)
HR (1) HRP20141134T1 (ru)
IL (1) IL208788A (ru)
MX (1) MX2010012432A (ru)
MY (1) MY153109A (ru)
NZ (1) NZ588794A (ru)
PE (2) PE20091900A1 (ru)
PL (1) PL2273981T3 (ru)
PT (1) PT2273981E (ru)
RS (1) RS53775B1 (ru)
SG (1) SG190643A1 (ru)
SI (1) SI2273981T1 (ru)
TW (1) TWI501789B (ru)
UA (1) UA102547C2 (ru)
WO (1) WO2009139504A2 (ru)
ZA (1) ZA201008115B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
CN103920156B (zh) * 2014-04-04 2016-06-01 成都科特包衣技术有限公司 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法
CN106511313B (zh) * 2016-10-21 2019-06-07 浙江为康制药有限公司 西洛他唑缓释胶囊组合物及其制备方法
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
CA2503121A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
ATE389396T1 (de) * 2002-12-20 2008-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
JP5112619B2 (ja) * 2004-05-20 2013-01-09 大塚製薬株式会社 固形医薬製剤
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
US8187633B2 (en) * 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
WO2007105229A1 (en) * 2006-03-14 2007-09-20 Panacea Biotec Ltd. Controlled release pharmaceutical composition and process thereof
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008054121A1 (en) * 2006-10-30 2008-05-08 Hanall Pharmaceutical Company. Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
BRPI0817822A2 (pt) * 2007-10-19 2015-03-31 Otsuka Pharma Co Ltd Preparação sólida farmacêutica do tipo matriz
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol

Also Published As

Publication number Publication date
EA022712B1 (ru) 2016-02-29
TW201000152A (en) 2010-01-01
EP2273981B1 (en) 2014-11-05
CA2722244C (en) 2016-09-13
CO6321223A2 (es) 2011-09-20
JP5552434B2 (ja) 2014-07-16
ZA201008115B (en) 2012-01-25
ES2524261T3 (es) 2014-12-04
WO2009139504A3 (en) 2010-09-30
KR101585280B1 (ko) 2016-01-13
US20110091535A1 (en) 2011-04-21
PE20140962A1 (es) 2014-08-15
KR20110007255A (ko) 2011-01-21
EP2273981A2 (en) 2011-01-19
TWI501789B (zh) 2015-10-01
CN102119024A (zh) 2011-07-06
NZ588794A (en) 2012-07-27
HK1149497A1 (en) 2011-10-07
MX2010012432A (es) 2010-12-06
AR071706A1 (es) 2010-07-07
MY153109A (en) 2014-12-31
IL208788A0 (en) 2010-12-30
HRP20141134T1 (hr) 2015-01-30
DK2273981T3 (en) 2014-11-24
AU2009247156B2 (en) 2013-10-24
CA2722244A1 (en) 2009-11-19
ECSP10010683A (es) 2011-01-31
AU2009247156A1 (en) 2009-11-19
UA102547C2 (ru) 2013-07-25
SG190643A1 (en) 2013-06-28
CN104971037A (zh) 2015-10-14
PT2273981E (pt) 2015-01-02
CY1115955T1 (el) 2017-01-25
SI2273981T1 (sl) 2015-01-30
BRPI0912656A2 (pt) 2016-01-26
CL2009001183A1 (es) 2010-06-18
RS53775B1 (en) 2015-06-30
WO2009139504A2 (en) 2009-11-19
IL208788A (en) 2016-05-31
PE20091900A1 (es) 2009-12-31
PL2273981T3 (pl) 2015-04-30
JP2011520774A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
EA201001529A1 (ru) Способ и композиция для лечения mif-опосредованных расстройств
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201170703A1 (ru) Производные адамантилбензамида
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201071309A1 (ru) Твердая фармацевтическая композиция
DE602006002260D1 (de) Insektenabweisende zusammensetzungen mit verzögerter freisetzung
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
EA201100286A1 (ru) Композиция кветиапина
EA201170512A1 (ru) Композиция для перорального введения
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
TR200902923T2 (tr) Megestrol maddenin farmasötik olarak kararlı bir süspansiyonu.
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
EA201100753A1 (ru) Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU